These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35047478)

  • 1. Synthesis of Novel Suramin Analogs With Anti-Proliferative Activity
    Parveen N; Lin YL; Chou RH; Sun CM; Yu C
    Front Chem; 2021; 9():764200. PubMed ID: 35047478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suramin derivatives play an important role in blocking the interaction between FGF1 and FGFRD2 to inhibit cell proliferation.
    Parveen N; Lin YL; Khan MI; Chou RH; Sun CM; Yu C
    Eur J Med Chem; 2020 Nov; 206():112656. PubMed ID: 32827875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suramin blocks interaction between human FGF1 and FGFR2 D2 domain and reduces downstream signaling activity.
    Wu ZS; Liu CF; Fu B; Chou RH; Yu C
    Biochem Biophys Res Commun; 2016 Sep; 477(4):861-867. PubMed ID: 27387234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M; van den Berg HW; Lynch M
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking studies, biological evaluation and synthesis of novel 3-mercapto-1,2,4-triazole derivatives.
    Ghanaat J; Khalilzadeh MA; Zareyee D
    Mol Divers; 2021 Feb; 25(1):223-232. PubMed ID: 32067134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, Anti-Proliferative, Anti-microbial, Anti-Angiogenic Activity and
    Ünver H; Berber B; Demirel R; Koparal AT
    Anticancer Agents Med Chem; 2019; 19(13):1658-1669. PubMed ID: 30887930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis of Inhibition of the Pioneer Transcription Factor NF-Y by Suramin.
    Nardone V; Chaves-Sanjuan A; Lapi M; Airoldi C; Saponaro A; Pasqualato S; Dolfini D; Camilloni C; Bernardini A; Gnesutta N; Mantovani R; Nardini M
    Cells; 2020 Oct; 9(11):. PubMed ID: 33138093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative.
    Finch PW; Yee LK; Chu MY; Chen TM; Lipsky MH; Maciag T; Friedman S; Epstein MH; Calabresi P
    Pharmacology; 1997 Dec; 55(6):269-78. PubMed ID: 9413855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion.
    Gill JS; Windebank AJ
    Neuroscience; 1998 Dec; 87(4):855-60. PubMed ID: 9759973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin Targets the Conserved Ligand-Binding Pocket of Human Raf1 Kinase Inhibitory Protein.
    Guo C; Wu Z; Lin W; Xu H; Chang T; Dai Y; Lin D
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33670019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression.
    Li H; Li H; Qu H; Zhao M; Yuan B; Cao M; Cui J
    Cancer Cell Int; 2015; 15():52. PubMed ID: 26052253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
    Kalli KR; Bradley SV; Fuchshuber S; Conover CA
    Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
    Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
    Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, Characterization, Molecular Docking, In Vitro Biological Evaluation and In Vitro Cytotoxicity Study of Novel Thiazolidine-4-One Derivatives as Anti-Breast Cancer Agents.
    Kadhim ZY; Alqaraghuli HGJ; Abd MT
    Anticancer Agents Med Chem; 2021; 21(17):2397-2406. PubMed ID: 33797379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Redesign of Suramin Analogs for Novel Antimicrobial Lead Development.
    Dey D; Ramakumar S; Conn GL
    J Chem Inf Model; 2021 Sep; 61(9):4442-4454. PubMed ID: 34516120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NMR solution structure of human epidermal growth factor (hEGF) at physiological pH and its interactions with suramin.
    Huang HW; Mohan SK; Yu C
    Biochem Biophys Res Commun; 2010 Nov; 402(4):705-10. PubMed ID: 21029725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression.
    Mills GB; Zhang N; May C; Hill M; Chung A
    Cancer Res; 1990 May; 50(10):3036-42. PubMed ID: 1692253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, Molecular Docking Study and in vitro Anticancer Activity of Tetrazole Linked Benzochromene Derivatives.
    Gorle S; Maddila S; Maddila SN; Naicker K; Singh M; Singh P; Jonnalagadda SB
    Anticancer Agents Med Chem; 2017; 17(3):464-470. PubMed ID: 27357544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
    Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
    Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.